Phase I trial of weekly bortezomib (Velcade) in the treatment of patients with refractory multiple myeloma

Trial Profile

Phase I trial of weekly bortezomib (Velcade) in the treatment of patients with refractory multiple myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2013

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2009 Trial phase changed from I to II as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Additional lead centre and lead investigator identified as reported by ClinicalTrials.gov, last updated 22-1-2009.
    • 22 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top